Onco Actu du 9 mars 2018

	2. Etiologie
Binge watching TV could increase bowel cancer risk in men [Cancer Research UK] It’s interesting that only men who watched a lot of TV had an increased risk of bowel cancer, but not women. The study didn’t look at this directly, but it could be because men might smoke, drink and eat more unhealthily than women while watching TV.
	3.1 Prévention - Tabac
Report: Big tobacco is targeting the world's most vulnerable to increase profits [ACS] Africa and the Middle East are at a tipping point for avoiding epidemic numbers of preventable morbidity and mortality.
Austrian no-smoking petition against government reaches 500,000 mark [Reuters] Half a million Austrians have signed a petition calling for a smoking ban in bars and restaurants, embarrassing the ruling coalition of conservatives and far right that has championed both direct democracy and the right to smoke.
	4.1 Dép., diag. & prono. - Prostate
Prostate cancer screening: massive study gets minimal coverage. Why? [HealthNewsReview] It stands in stark contrast to the mega-coverage we’ve documented for many years on other prostate cancer screening studies that are typically much less rigorous — and which often trumpet an imbalanced, pro-screening message about prostate cancer. Not that the British study advocates against screening, but it certainly brings many of its limitations into focus.
	5. Traitements
Multidisciplinary Team Care is Associated with Improved Survival in Metastatic GCT [ESMO] Data support reconstructing health delivery models to enhance value and improve clinical outcomes.
The 30 Year Quest To Tame The 'Wily' Cancer Gene [NPR] I asked McCormick if his decades-long quest to conquer RAS was akin to Captain Ahab's obsessive quest for the great white whale, Moby Dick. "Not yet!" he replied with a laugh.
	5.1 Traitements - Pré-clinique
CRISPR-based system identifies important new drug targets in a deadly leukemia [Cold Spring Harbor Lab] CSHL Associate Professor Christopher Vakoc, M.D., Ph.D., and colleagues now report that they can stop the growth of MEF2C-driven AML cells by blocking either of two target enzymes, known as LKB1 and salt-inducible kinase. The chemicals that the team used to interfere with the enzymes are small molecules that have the potential to be developed into drugs, Vakoc says.
	5.12 Immunothérapies
New Clinical Trials Test Immunotherapy for Cervical Cancer [Dana-Farber Cancer Institute] Konstantinopoulos is conducting a trial that pairs the immunotherapy drug atezolizumab (Tecentriq) with an antiangiogenic agent called bevacizumab, which blocks cancer cells from forming the new blood vessels they need to grow.
PD-L1 in Extracellular Vesicles May Help Glioblastoma Evade Immunotherapies [The Scientist] The discovery suggests that the immune checkpoint can operate at a further distance from tumor cells than previously believed.
	5.12.1 Immunothérapies - partenariats
In another blockbuster cancer deal, Merck lays out up to $5.8B for half of Eisai's Lenvima [FiercePharma] For Merck, it’s the second blockbuster cancer deal its pulled off since July, when it teamed up with PARP drugmaker AstraZeneca on an $8.5 billion collaboration for Lynparza.
	5.12.2 Immunothérapies - CAR-T
Juno, WuXi JV gets a $90M round as China’s CAR-T pioneers fly high with fresh cash [EndPoints] It’s a marriage of Juno’s hard-won CAR-T development experience and WuXi’s powerhouse manufacturing capabilities.
	5.2 Pharma
UK launch for Europe’s first Herceptin biosimilar [PharmaTimes] MSD has launched in the UK Europe’s first biosimilar to Roche/Genentech’s Herceptin, providing an alternative option for treating early breast cancer, metastatic breast cancer and metastatic gastric cancer.
VBL Therapeutics sees Avastin-VB-111 phase 3 combo flop in brain cancer [FierceBiotech] Israeli biotech VBL Therapeutics has joined a long and depressing line of companies that have failed to move the needle in a test against a form of aggressive brain tumor.
Failure in pivotal PhIII brain cancer trial drags Israel’s VBL Therapeutics down [EndPoints] The trial, which compared a combo of VB-111 and Roche’s Avastin (bevacizumab) against Avastin alone among patients with recurrent glioblastoma, failed the primary endpoint of overall survival.
	5.2.3 Pharma - économie
Cyteir Bags $29M to Tap “Self Destruct” in Cancers, Immune Diseases [Xconomy] Though AID helps cancers grow, it also damages their DNA, Mills says. To repair that damage, cancers use another protein called RAD51. A Cyteir cancer drug would interfere with that repair protein, limiting its ability to fix damaged DNA. As a result, AID activity is unchecked and destroys the cancer cell, Mills says.
Beyond Flatiron: The Rising Power Of Oncology Clinical Data Companies [Forbes] The limiting factor for commercialization could soon be not whether a drug is approved by the FDA, based on clinical trial data, but whether it’s validated by oncology clinical data companies, based on real-world performance.
	5.3 Traitements - FDA, EMA, NICE...
Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone [EMA] Ongoing clinical study shows an increased risk of death and fractures with the combination.
	5.3.4 Traitements - AMM (FDA, EMA,...)
FDA Approves Apalutamide for Some Men with Prostate Cancer [NCI] "It's highly likely that apalutamide would be active" in men with metastatic castration-resistant prostate cancer, Dr. Dahut speculated. Trials to evaluate apalutamide in this patient population are already underway, Dr. Smith noted.
	5.4 Traitements - Economie
Bringing down the cost of cancer treatment [Nature] To address the problem, some EU countries have banded together to create a united front against pharmaceutical companies. The Netherlands, Belgium, Austria and Luxembourg have formed one such union. Half a dozen Mediterranean countries hope to do the same.
	6.1 Observation
Choice of lung cancer treatment could be affecting survival [Cancer Research UK] Surgery, radiotherapy and chemotherapy rates vary across England, and survival is best where they are highest. Differences in factors like patient age or sex didn’t.
A Real News Story Of Hope: Impressive Decline in Melanoma Incidence In Young Women Will Result In A World With Less Cancer [Dr. Len's Blog] The report found among young white women ages 15 to 24 , the incidence of melanoma has declined an average of 5.5% per year from January 2005 through December 2014. Not 5.5% over those ten years but 5.5 % PER YEAR. That’s remarkable, to say the least.